Definium Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Definium Therapeutics (DFTX) granted stock options to three new non-executive employees, totaling 56,650 shares. The options, priced at the closing share price on the grant date, will vest over four years. The company's Compensation Committee approved the awards, aligning with Nasdaq rules. This reflects Definium's focus on attracting talent for its late-stage clinical pipeline.
Oppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.
The FDA will hold a public hearing on psychedelic drugs' therapeutic use, part of a Trump administration push to accelerate development. The FDA has issued priority vouchers to three companies. The hearing will discuss practical issues like training and safety data. FDA officials published a framework for psychedelic drug approval, suggesting flexible trial designs. Industry executives say this could reduce regulatory delays and benefit companies like AtaiBeckley, Compass Pathways, and Definium
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning DFTX (Definium Therapeutics, Inc.). Coverage has skewed bullish: 8 bullish, 2 neutral, and 1 bearish.
Recent DFTX coverage spans financial news, corporate actions and technology.
In the last 30 days, DFTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($722K). The most active reporter was Barrow Robert, Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor dilution risk and modest incentive signal; unlikely to move price materially.
Analyst price target increase may boost investor sentiment and support price appreciation.
Direct involvement could boost visibility and funding prospects.
Positive trial data may trigger a sharp price rally for DFTX as investors anticipate regulatory filing and potential market entry.
Strong positive catalyst from successful trial results.
AlphAI scores every news story that mentions DFTX with an AI model for sentiment and relevance, and aggregates insider trades from Definium Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Definium Therapeutics (DFTX) granted stock options to three new non-executive employees, totaling 56,650 shares. The options, priced at the closing share price on the grant date, will vest over four years. The company's Compensation Committee approved the awards, aligning with Nasdaq rules. This reflects Definium's focus on attracting talent for its late-stage clinical pipeline.
1 min readOppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.
1 min readThe FDA will hold a public hearing on psychedelic drugs' therapeutic use, part of a Trump administration push to accelerate development. The FDA has issued priority vouchers to three companies. The hearing will discuss practical issues like training and safety data. FDA officials published a framework for psychedelic drug approval, suggesting flexible trial designs. Industry executives say this could reduce regulatory delays and benefit companies like AtaiBeckley, Compass Pathways, and Definium
2 min readDefinium Therapeutics (DFTX) reported that its LSD-based treatment reduced anxiety symptoms by 9.8 points on a 56-point scale, compared to 4.7 for placebo. The company's shares, already up 190% this year, rose further on the news.
1 min readUS futures decline as tech stocks, particularly AI-linked ones, fall due to concerns over slower AI development. Nvidia, Tesla, and Meta are among the decliners, while oil prices rise. Brent crude approaches $108/barrel. Bond yields show mixed movements. Several companies, including Corning and Scholar Rock, see significant premarket moves. Fed and BoJ rate decisions are upcoming.
3 min readDefinium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.
2 min readDefinium Therapeutics (DFTX) granted 56,650 stock options to three new non-executive employees. The options vest over four years, with 25% vesting after one year. The grants were approved by the Compensation Committee and comply with NASDAQ rules. Definium focuses on psychiatric and neurological disorder treatments.
2 min readDefinium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.
1 min readBarrow Robert (Chief Executive Officer) sold 19,023 shares of Definium Therapeutics, Inc. (DFTX) at $37.94 ($0.72M total) on 2026-09-03 under a Rule 10b5-1 trading plan.
1 min readStifel reaffirmed a buy rating and $60 price target for Definium Therapeutics (DFTX), citing favorable regulatory feedback and upcoming clinical readouts. Insiders sold shares, while institutional investors increased holdings. Analysts' price targets range from $50 to $74.
2 min read
